Discover BeVigilant™ OraFusion™
Featured Products Promotional FeaturesPosted by: Dental Design 14th January 2024
BDIA Dental Showcase Excel 22nd-23rd March
With the BeVigilant™ OraFusion™ System, clinicians can get a simple and accurate assessment to aid in the early detection of oral cancer. The platform provides a semi-quantitative result at the point–of–care, reporting low, moderate or elevated levels of risk associated with oral cancer.
Current oral cancer survival rate is 50%, due to delayed detection and intervention. By detecting oral cancer in stage I or stage II, survival rates can increase dramatically – to an impressive 90%.
Dental practitioners, while diligent, may find early malignancy identification challenging, occasionally defaulting to a cautious approach. However, technological advancements in diagnostic methods, like the BeVigilant™ OraFusion™ system, empower clinicians to enhance early detection and dramatically improve their accuracy in assessing patients.
“Our mission revolves around elevating survival outcomes in oral cancer through early detection,” expressed Bill Brodie, CEO of Vigilant Biosciences.
Visit our stand on 22nd-23rd March at the upcoming BDIA Dental Showcase to find out how you can introduce BeVigilant™ OraFusion™ into your own clinical practice and help improve patient outcomes.
For more information, please visit https://totaltmj.co.uk/products/bevigilant-orafusion/,
call us on 1202 313702, or email us at info@totaltmj.co.uk
